Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective.

Abstract

INTRODUCTION Rivaroxaban is an oral direct factor Xa inhibitor that is noninferior to warfarin in the prevention of recurrent venous thromboembolism (VTE). Whether rivaroxaban is cost-effective in the prevention of recurrent VTE, however, is not known. MATERIAL AND METHODS To assess the cost effectiveness of rivaroxaban compared with warfarin in the… (More)
DOI: 10.1016/j.thromres.2013.09.015

Topics

  • Presentations referencing similar topics